Pharma Tech

ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial

Oct 28, 2026, 12:43 AM

Read Full Article → ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial

Translate article text

Choose a language and wait for the translated text.

Reduced-frequency checkpoint inhibitor treatment could not demonstrate non-inferior PFS and showed a signal of worse survival.